Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: A double-blind, randomised, placebo-controlled trial

The Lancet Infectious Diseases

Volumn 11, Issue 12, 2011, Pages 933-941

  Parkes Ratanshi, Rosalind ^a,b,c   Wakeham, Katie ^a,b   Levin, Jonathan ^a,d   Namusoke, Deodata ^e   Whitworth, James ^f   Coutinho, Alex ^e,g   Mugisha, Nathan Kenya ^h   Grosskurth, Heiner ^a,i   Kamali, Anatoli ^a   Lalloo, David G ^b  

^a UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

^b LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^e The AIDS Support Organisation ^*  (Uganda)

^f WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^g Infectious Diseases Institute   (Uganda)

^h MINISTRY OF HEALTH   (Uganda)

ⁱ LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN; CLOTRIMAZOLE; FLUCONAZOLE; KETOCONAZOLE; NYSTATIN; PLACEBO;

ABDOMINAL PAIN; ADULT; ANEMIA; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; CRYPTOCOCCOSIS; DISABILITY; DOUBLE BLIND PROCEDURE; ESOPHAGUS CANDIDIASIS; FEMALE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; NAUSEA; OROPHARYNX CANDIDIASIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; UGANDA; VAGINA CANDIDIASIS;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIBIOTIC PROPHYLAXIS; ANTIFUNGAL AGENTS; CD4 LYMPHOCYTE COUNT; CRYPTOCOCCOSIS; FEMALE; FLUCONAZOLE; HIV SEROPOSITIVITY; HIV-1; HUMANS; INCIDENCE; MALE; MIDDLE AGED; TREATMENT OUTCOME; UGANDA; YOUNG ADULT;

EID: 81855185571     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(11)70245-6     Document Type: Article

References (39)

1. French N, Gray K, Watera C, et al. Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS 2002, 16:1031-1038.
2. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009, 23:525-530.
3. Kambugu A, Meya DB, Rhein J, et al. Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis 2008, 46:1694-1701.
4. Bicanic T, Wood R, Meintjes G, et al. High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin Infect Dis 2008, 47:123-130.
5. Rex JH, Larsen RA, Dismukes WE, Cloud GA, Bennett JE Catastrophic visual loss due to Cryptococcus neoformans meningitis. Medicine (Baltimore) 1993, 72:207-224.
6. Sloan D, Dlamini S, Paul N, Dedicoat M Treatment of acute cryptococcal meningitis in HIV infected adults, with an emphasis on resource-limited settings. Cochrane Database Syst Rev 2008, 4. CD005647.
7. Schaars CF, Meintjes GA, Morroni C, Post FA, Maartens G Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazole. BMC Infect Dis 2006, 6:118.
8. Bicanic T, Meintjes G, Wood R, et al. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis 2007, 45:76-80.
9. Powderly WG, Finkelstein D, Feinberg J, et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med 1995, 332:700-705.
10. Smith DE, Bell J, Johnson M, et al. A randomized, double-blind, placebo-controlled study of itraconazole capsules for the prevention of deep fungal infections in immunodeficient patients with HIV infection. HIV Med 2001, 2:78-83.
11. Nightingale SD, Cal SX, Peterson DM, et al. Primary prophylaxis with fluconazole against systemic fungal infections in HIV-positive patients. AIDS 1992, 6:191-194.
12. Ammassari A, Linzalone A, Murri R, Marasca G, Morace G, Antinori A Fluconazole for primary prophylaxis of AIDS-associated cryptococcosis: a case-control study. Scand J Infect Dis 1995, 27:235-237.
13. Cantey PT, Stephens DS, Rimland D Prevention of cryptococcosis in HIV-infected patients with limited access to highly active antiretroviral therapy: evidence for primary azole prophylaxis. HIV Med 2005, 6:253-259.
14. Newton JA, Tasker SA, Bone WD, et al. Weekly fluconazole for the suppression of recurrent thrush in HIV-seropositive patients: impact on the incidence of disseminated cryptococcal infection. AIDS 1995, 9:1286-1287.
15. McKinsey DS, Wheat LJ, Cloud GA, et al. Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled, double-blind study. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 1999, 28:1049-1056.
16. Havlir DV, Dube MP, McCutchan JA, et al. Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS. Clin Infect Dis 1998, 27:1369-1375.
17. Quagliarello VJ, Viscoli C, Horwitz RI Primary prevention of cryptococcal meningitis by fluconazole in HIV-infected patients. Lancet 1995, 345:548-552.
18. Nelson MR, Fisher M, Cartledge J, Rogers T, Gazzard BG The role of azoles in the treatment and prophylaxis of cryptococcal disease in HIV infection. AIDS 1994, 8:651-654.
19. Chang LW, Phipps WT, Kennedy GE, Rutherford GW Antifungal interventions for the primary prevention of cryptococcal disease in adults with HIV. Cochrane Database Syst Rev 2005, 3. CD004773.
20. Chetchotisakd P, Sungkanuparph S, Thinkhamrop B, Mootsikapun P, Boonyaprawit P A multicentre, randomized, double-blind, placebo-controlled trial of primary cryptococcal meningitis prophylaxis in HIV-infected patients with severe immune deficiency. HIV Med 2004, 5:140-143.
21. Chariyalertsak S, Supparatpinyo K, Sirisanthana T, Nelson KE A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand. Clin Infect Dis 2002, 34:277-284.
22. Ives NJ, Gazzard BG, Easterbrook PJ The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART) in a London clinic. J Infect 2001, 42:134-139.
23. Dromer F, Mathoulin-Pelissier S, Fontanet A, Ronin O, Dupont B, Lortholary O Epidemiology of HIV-associated cryptococcosis in France (1985-2001): comparison of the pre- and post-HAART eras. AIDS 2004, 18:555-562.
24. Mirza SA, Phelan M, Rimland D, et al. The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000. Clin Infect Dis 2003, 36:789-794.
25. Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector. Progress Report 2008, 1-140. WHO, UNICEFUNICEF, UNAIDSUNAIDS, World Health Organization, Geneva.
26. Lawn SD, Bekker LG, Myer L, Orrell C, Wood R Cryptococcocal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programme. AIDS 2005, 19:2050-2052.
27. McCarthy KM, Morgan J, Wannemuehler KA, et al. Population-based surveillance for cryptococcosis in an antiretroviral-naive South African province with a high HIV seroprevalence. AIDS 2006, 20:2199-2206.
28. Cleves MA Analysis of multiple failure-time data with Stata. Stata J 1999, 49(ssa 13):30-39.
29. Braitstein P, Boulle A, Nash D, et al. Gender and the use of antiretroviral treatment in resource-constrained settings: findings from a multicenter collaboration. J Womens Health (Larchmt) 2008, 17:47-55.
30. Liechty CA, Solberg P, Were W, et al. Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop Med Int Health 2007, 12:929-935.
31. Jarvis JN, Lawn SD, Vogt M, Bangani N, Wood R, Harrison TS Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis 2009, 48:856-862.
32. Manosuthi W, Athichathanabadi C, Uttayamakul S, Phoorisri T, Sungkanuparph S Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole. BMC Infect Dis 2007, 7:14.
33. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006, 367:817-824. for the Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration, ART Cohort Collaboration (ART-CC) groupsART Cohort Collaboration (ART-CC) groups.
34. AIDS epidemic update UNAIDS/WHO, (accessed Sept 30, 2011). http://dataunaidsorg/pub/Report/2009/JC1700_Epi_Update_2009_enpdf.
35. Parkes-Ratanshi R, Bufumbo L, Nyanzi-Wakholi B, et al. Barriers to starting ART and how they can be overcome: individual and operational factors associated with early and late start of treatment. Trop Med Int Health 2010, 15:1347-1356.
36. Lawn SD, Campbell L, Kaplan R, et al. Time to initiation of antiretroviral therapy among patients with HIV-associated tuberculosis in Cape Town, South Africa. J Acquir Immune Defic Syndr 2011, 57:136-140.
37. Meya D, Manabe Y, Castelnuovo B, et al. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or =100 cells/microL who start HIV therapy in resource-limited settings. Clin Infect Dis 2010, 51:448-455.
38. Micol R, Tajahmady A, Lortholary O, et al. Cost-effectiveness of primary prophylaxis of AIDS associated cryptococcosis in Cambodia. PLoS One 2010, 5:e13856.
39. Essential prevention and care interventions for adults and adolescents living with HIV in resource limited settings 2008, 20-23. WHO, World Health Organization, Geneva.